Integrum (STO:INTEG B) First Quarter 2025 Results
Key Financial Results
- Revenue: kr19.8m (down 4.6% from 1Q 2024).
- Net loss: kr9.41m (loss widened by 229% from 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Integrum Earnings Insights
Looking ahead, revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Medical Equipment industry in Sweden.
Performance of the Swedish Medical Equipment industry.
The company's shares are down 41% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 3 warning signs for Integrum that you should be aware of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:INTEG B
Integrum
Researches, develops, and sells various systems for bone-anchored prostheses.
Flawless balance sheet with high growth potential.
